Literature DB >> 21843850

Reporting quality of conference abstracts on randomised controlled trials in gerontology and geriatrics: a cross-sectional investigation.

Eva Mann1, Gabriele Meyer.   

Abstract

Without transparent reporting of how a randomised controlled trial was designed and conducted and of the methods used, its internal validity cannot be assessed by the reader. A congress abstract is often the only source providing information about a trial. In January 2008, an extended CONSORT statement on abstract reporting was published. Its impact has yet to be evaluated. Using a slightly modified CONSORT checklist comprising 17 items, we thus investigated the reporting quality of randomised controlled trials published in the book of abstracts presented at the World Congress of Geriatrics and Gerontology in Paris in July 2009. A total of n=4,416 abstracts was screened for inclusion; n=129 met the inclusion criteria. The overall quality of the abstracts was remarkably poor. The primary outcome was mentioned in 34/129 abstracts (26%), none of the abstracts reported on the procedure of random allocation of participants or clusters, 21/129 abstracts (16%) reported some kind of blinding, and the attrition rate was mentioned in only 12/129 abstracts (9%). The majority of abstracts fulfilled two items: description of intended intervention for each group (102/129; 79%) and general interpretation of results (107/129; 83%). Trial status was reported in all abstracts. Both journal editors and committees organising congresses are requested to define the use of the CONSORT statement as a prerequisite in their guidelines for authors and to instruct reviewers to conduct compliance checks. Medical associations should finally endorse the indispensability of the CONSORT statement and publish it in their journals. Otherwise the intended benefits cannot be fully generated.
Copyright © 2010. Published by Elsevier GmbH.

Entities:  

Mesh:

Year:  2010        PMID: 21843850     DOI: 10.1016/j.zefq.2010.07.011

Source DB:  PubMed          Journal:  Z Evid Fortbild Qual Gesundhwes        ISSN: 1865-9217


  6 in total

Review 1.  Authors report lack of time as main reason for unpublished research presented at biomedical conferences: a systematic review.

Authors:  Roberta W Scherer; Cesar Ugarte-Gil; Christine Schmucker; Joerg J Meerpohl
Journal:  J Clin Epidemiol       Date:  2015-02-13       Impact factor: 6.437

2.  Assessment of adherence to the CONSORT statement for quality of reports on randomized controlled trial abstracts from four high-impact general medical journals.

Authors:  Saurav Ghimire; Eunjung Kyung; Wonku Kang; Eunyoung Kim
Journal:  Trials       Date:  2012-06-07       Impact factor: 2.279

3.  Reporting quality of randomised controlled trial abstracts presented at the SLEEP Annual Meetings: a cross-sectional study.

Authors:  Fang Hua; Qiao Sun; Tingting Zhao; Xiong Chen; Hong He
Journal:  BMJ Open       Date:  2019-07-16       Impact factor: 2.692

4.  Refining a taxonomy for guideline implementation: results of an exercise in abstract classification.

Authors:  Danielle Mazza; Phillip Bairstow; Heather Buchan; Samantha Paubrey Chakraborty; Oliver Van Hecke; Cathy Grech; Ilkka Kunnamo
Journal:  Implement Sci       Date:  2013-03-15       Impact factor: 7.327

Review 5.  Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies.

Authors:  Shanthi Sivendran; Kristina Newport; Michael Horst; Adam Albert; Matthew D Galsky
Journal:  Trials       Date:  2015-08-08       Impact factor: 2.279

6.  A multiyear systematic survey of the quality of reporting for randomised trials in dentistry, neurology and geriatrics published in journals of Spain and Latin America.

Authors:  Vivienne C Bachelet; María S Navarrete; Constanza Barrera-Riquelme; Víctor A Carrasco; Matías Dallaserra; Rubén A Díaz; Álvaro A Ibarra; Francisca J Lizana; Nicolás Meza-Ducaud; Macarena G Saavedra; Camila Tapia-Davegno; Alonso F Vergara; Julio Villanueva
Journal:  BMC Med Res Methodol       Date:  2021-07-26       Impact factor: 4.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.